Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect of BriaCell Therapeutics Corp. from 31 Jul 2023 to 31 Oct 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
BriaCell Therapeutics Corp. quarterly and annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD history and change rate from 31 Jul 2023 to 31 Oct 2025.
  • BriaCell Therapeutics Corp. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending 31 Oct 2025 was $7,779,796, a 258% decline year-over-year.
  • BriaCell Therapeutics Corp. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2025 was $9,631,719.
  • BriaCell Therapeutics Corp. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2024 was $20,389,003, a 3% decline from 2023.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Change (%)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Annual (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Annual Change (%)

BriaCell Therapeutics Corp. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $7,779,796 -$12,709,972 -258% 01 Aug 2025 31 Oct 2025 10-Q 11 Dec 2025 2026 Q1
Q3 2024 $4,930,176 +$12,535,421 01 Aug 2024 31 Oct 2024 10-Q 11 Dec 2025 2026 Q1
Q3 2023 $7,605,245 01 Aug 2023 31 Oct 2023 10-Q 16 Dec 2024 2025 Q1

BriaCell Therapeutics Corp. Annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $9,631,719 +$30,020,722 01 Aug 2024 31 Jul 2025 10-K 16 Oct 2025 2025 FY
2024 $20,389,003 -$598,443 -3% 01 Aug 2023 31 Jul 2024 10-K 16 Oct 2025 2025 FY
2023 $19,790,560 01 Aug 2022 31 Jul 2023 10-K 29 Oct 2024 2024 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.